The aim of this study was to evaluate the ability of a prototype intraoperative mini g-camera, the CarolIReS, with a 50 · 50 mm field of view, to precisely localize sentinel lymph nodes (SLNs) and to determine their depth in a series of patients with infiltrative breast cancer requiring SLN excision. Methods: With the use of phantoms, the broadness of the signal of an acquired projection was shown to linearly depend on its distance from the collimator. A preclinical ex vivo study of 25 excised SLNs demonstrated that SLN size did not influence depth estimation. The minimum activity threshold for successful use of the proposed method was determined. After a preoperative radioisotope injection and lymphoscintigraphy, the SLN was localized in a series of 11 patients using both the mini g-camera and a g-probe. During surgery, a ruler was used to measure the depth of all SLNs before their excision. Results: Using the measured linear dependence of image broadness, we found that the expected SLN anatomic depth was compatible with its measured depth during surgery. Conclusion: This study showed that the mini g-camera efficiently estimated the location of SLNs in 3 dimensions.Key Words: breast cancer; lymphoscintigraphy; intraoperative gamma-camera; sentinel lymph node; CarolIReS Mostt ypes of lymphophile cancers require assessment of regional lymph nodes for staging the tumor, determining prognosis, and devising therapeutic strategies. Complete lymph node dissections are frequently associated with significant morbidity. Combining diagnostic advantages with decreased morbidity (1,2), the sentinel lymph node (SLN) procedure represents one of the most recent advances in surgical oncology. It consists of the identification and removal of SLNs, which are lymph nodes that receive lymphatic drainage directly from the primary tumor. The SLN procedure is now a widely accepted method of lymph node staging for selected cases of invasive breast cancer (3,4) and cutaneous melanoma (5). The concept is also being evaluated in numerous other types of cancer, including pelvic gynecologic (vulval, cervical, and endometrial) (6-9), prostate (10), colon (11), gastric (12) and thyroid (13) cancer. In all cases, successful adaptation of the SLN procedure implies that the operator has a high identification rate and a low false-negative rate. For SLN identification, in addition to the peroperative injection of a blue dye, a 99m Tc-radiomarked colloidal solution is generally injected the day before or the day of the surgery and 2 planar scintigraphic images are taken in a nuclear medicine department. In a recent metaanalysis (14) including 69 trials and 8,059 patients with low-risk breast cancer, the proportion of patients with successfully mapped SLNs ranged from 41% to 100%, with more than 50% of the studies reporting a rate under 90%. The false-negative rate ranged from 0% to 29%, averaging 7.3% overall. Significant inverse correlations were observed between the false-negative rate and the proportion of patients with successfully mapped SLN...